Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Metformin got secret of cancer treatment
Use of Metformin commonly used as the front-line treatment for type 2 diabetes improves survival for some breast cancer patients, and shows promise as a treatment for patients diagnosed with endometrial hyperplasia, according to the results of two new studies presented by researchers from the Perelman School of Medicine at the University of Pennsylvania at the American Society of Clinical Oncology (ASCO) Annual Meeting.
- Read more about Sun Pharma to sell US based manufacturing unit
Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) announced that as a part of its manufacturing consolidation in the US, one of its wholly owned subsidiaries has entered into an agreement with Frontida BioPharm, Inc. (“Frontida”) for divestment of its two oral solid dosage manufacturing facilities located at Philadelphia, PA, and Aurora, IL both in the US, along with 15 related pharmaceutical products.
- Read more about Bayer, Orion expand global clinical development programme with new phase III study ARASENS for BAY-1841788
Bayer and Orion Corporation announced the expansion of the global clinical development programme for the investigational androgen receptor (AR) antagonist BAY-1841788 (ODM-201) in the area of prostate cancer. A new phase III study ARASENS will evaluate the compound in combination with standard androgen deprivation therapy (ADT) and the chemotherapy docetaxel in men with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are starting first line hormone therapy.
- Read more about Novartis drug Afinitor® receives EU approval to treat gastrointestinal and lung neuroendocrine tumors
Novartis announced that the European Commission has approved Afinitor® (everolimus) tablets for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin in adults with progressive disease. Afinitor is the first approved therapy in all 28 member states of the European Union (EU), plus Iceland and Norway, for this type of lung NET, and one of very few treatment options available for this type of GI NET.
6 June 2016

QIAGEN extend offer period for the acquisition of Exiqon A/S

QIAGEN N.V. announced another extension of the Offer Period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN N.V. had published a conditional, voluntary public tender offer for the shares in Exiqon A/S, in which the shareholders were offered a cash amount of DKK 18 for each share held in Exiqon A/S. This Offer Period had been extended on 19 May 2016, its terms and conditions remained unchanged. In accordance with the Offer, the extended Offer Period expired yesterday on 2 June 2016 at 23.59 (CET).
- Read more about Shire combine with Baxalta creating global biotech leader in rare diseases
Shire plc, a leading global biotechnology company, completed its previously announced combination with Baxalta Incorporated, creating the leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions.
- Read more about Soon, Animal Testing will be history in India
Government of India is considering to replace some animal tests with alternative methods in rabbits, guinea pigs or mice with respect to the approval of new drugs and therefore they are looking for replacements in Indian situation.

[adsense:336x280:8701650588]
- Read more about Achievements of India Health Ministry during the last two years
Department of Pharmaceuticals, ministry of health & Family welfare have made important advances in last two years. Which are as follows:
- Read more about FDA grant Rare Pediatric Disease Designation to Therabron Therapeutic’s rhCC10
Therabron Therapeutics, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to rhCC10 (recombinant human Club Cell 10 kDa Protein), the company’s lead product candidate,for the prevention of bronchopulmonary dysplasia and chronic respiratory morbidity (CRM) in preterm infants. The Rare Pediatric Disease Designation supplements the Fast Track Designation recently granted by the FDA for rhCC10. This program has also previously been granted Orphan Status by both the US and EU Health Authorities.
- Read more about Janssen Pharma New Idylla™ Ebola Virus Triage Test Grant Authorization by U.S. FDA
As part of Johnson & Johnson’s commitment to combat Ebola, Janssen Pharmaceutica NV announced that the Idylla™ Ebola Virus Triage Test (Idylla™ EBOV Test) was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). The Idylla™ Ebola Virus Triage Test is a diagnostic that detects the presence of the Ebola Zaire virus in patients with signs and symptoms of Ebola virus disease and was jointly developed by Janssen Diagnostics, a division of Janssen Pharmaceutica, Biocartis NV (Biocartis), and the Belgium Institute of Tropical Medicine.